Cargando…

In vivo Effects of a GPR30 Antagonist

Estrogen is central to many physiological processes throughout the human body. We have previously shown that the G protein-coupled receptor GPR30/GPER, in addition to classical nuclear estrogen receptors (ERα/β), activates cellular signaling pathways in response to estrogen. In order to distinguish...

Descripción completa

Detalles Bibliográficos
Autores principales: Dennis, Megan K., Burai, Ritwik, Ramesh, Chinnasamy, Petrie, Whitney K., Alcon, Sara N., Nayak, Tapan K., Bologa, Cristian G., Leitao, Andrei, Brailoiu, Eugen, Deliu, Elena, Dun, Nae J., Sklar, Larry A., Hathaway, Helen J., Arterburn, Jeffrey B., Oprea, Tudor I., Prossnitz, Eric R.
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864230/
https://www.ncbi.nlm.nih.gov/pubmed/19430488
http://dx.doi.org/10.1038/nchembio.168
_version_ 1782180758844080128
author Dennis, Megan K.
Burai, Ritwik
Ramesh, Chinnasamy
Petrie, Whitney K.
Alcon, Sara N.
Nayak, Tapan K.
Bologa, Cristian G.
Leitao, Andrei
Brailoiu, Eugen
Deliu, Elena
Dun, Nae J.
Sklar, Larry A.
Hathaway, Helen J.
Arterburn, Jeffrey B.
Oprea, Tudor I.
Prossnitz, Eric R.
author_facet Dennis, Megan K.
Burai, Ritwik
Ramesh, Chinnasamy
Petrie, Whitney K.
Alcon, Sara N.
Nayak, Tapan K.
Bologa, Cristian G.
Leitao, Andrei
Brailoiu, Eugen
Deliu, Elena
Dun, Nae J.
Sklar, Larry A.
Hathaway, Helen J.
Arterburn, Jeffrey B.
Oprea, Tudor I.
Prossnitz, Eric R.
author_sort Dennis, Megan K.
collection PubMed
description Estrogen is central to many physiological processes throughout the human body. We have previously shown that the G protein-coupled receptor GPR30/GPER, in addition to classical nuclear estrogen receptors (ERα/β), activates cellular signaling pathways in response to estrogen. In order to distinguish between the actions of classical estrogen receptors and GPR30, we have previously characterized a selective agonist of GPR30, G-1 (1). To complement the pharmacological properties of G-1, we sought to identify an antagonist of GPR30 that displays similar selectivity against the classical estrogen receptors. Here we describe the identification and characterization of a G-1 analog, G15 (2) that binds to GPR30 with high affinity and acts as an antagonist of estrogen signaling through GPR30. In vivo administration of G15 reveals that GPR30 contributes to both uterine and neurological responses initiated by estrogen. The identification of this antagonist will accelerate the evaluation of the roles of GPR30 in human physiology.
format Text
id pubmed-2864230
institution National Center for Biotechnology Information
language English
publishDate 2009
record_format MEDLINE/PubMed
spelling pubmed-28642302010-05-04 In vivo Effects of a GPR30 Antagonist Dennis, Megan K. Burai, Ritwik Ramesh, Chinnasamy Petrie, Whitney K. Alcon, Sara N. Nayak, Tapan K. Bologa, Cristian G. Leitao, Andrei Brailoiu, Eugen Deliu, Elena Dun, Nae J. Sklar, Larry A. Hathaway, Helen J. Arterburn, Jeffrey B. Oprea, Tudor I. Prossnitz, Eric R. Nat Chem Biol Article Estrogen is central to many physiological processes throughout the human body. We have previously shown that the G protein-coupled receptor GPR30/GPER, in addition to classical nuclear estrogen receptors (ERα/β), activates cellular signaling pathways in response to estrogen. In order to distinguish between the actions of classical estrogen receptors and GPR30, we have previously characterized a selective agonist of GPR30, G-1 (1). To complement the pharmacological properties of G-1, we sought to identify an antagonist of GPR30 that displays similar selectivity against the classical estrogen receptors. Here we describe the identification and characterization of a G-1 analog, G15 (2) that binds to GPR30 with high affinity and acts as an antagonist of estrogen signaling through GPR30. In vivo administration of G15 reveals that GPR30 contributes to both uterine and neurological responses initiated by estrogen. The identification of this antagonist will accelerate the evaluation of the roles of GPR30 in human physiology. 2009-06 /pmc/articles/PMC2864230/ /pubmed/19430488 http://dx.doi.org/10.1038/nchembio.168 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Dennis, Megan K.
Burai, Ritwik
Ramesh, Chinnasamy
Petrie, Whitney K.
Alcon, Sara N.
Nayak, Tapan K.
Bologa, Cristian G.
Leitao, Andrei
Brailoiu, Eugen
Deliu, Elena
Dun, Nae J.
Sklar, Larry A.
Hathaway, Helen J.
Arterburn, Jeffrey B.
Oprea, Tudor I.
Prossnitz, Eric R.
In vivo Effects of a GPR30 Antagonist
title In vivo Effects of a GPR30 Antagonist
title_full In vivo Effects of a GPR30 Antagonist
title_fullStr In vivo Effects of a GPR30 Antagonist
title_full_unstemmed In vivo Effects of a GPR30 Antagonist
title_short In vivo Effects of a GPR30 Antagonist
title_sort in vivo effects of a gpr30 antagonist
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864230/
https://www.ncbi.nlm.nih.gov/pubmed/19430488
http://dx.doi.org/10.1038/nchembio.168
work_keys_str_mv AT dennismegank invivoeffectsofagpr30antagonist
AT burairitwik invivoeffectsofagpr30antagonist
AT rameshchinnasamy invivoeffectsofagpr30antagonist
AT petriewhitneyk invivoeffectsofagpr30antagonist
AT alconsaran invivoeffectsofagpr30antagonist
AT nayaktapank invivoeffectsofagpr30antagonist
AT bologacristiang invivoeffectsofagpr30antagonist
AT leitaoandrei invivoeffectsofagpr30antagonist
AT brailoiueugen invivoeffectsofagpr30antagonist
AT deliuelena invivoeffectsofagpr30antagonist
AT dunnaej invivoeffectsofagpr30antagonist
AT sklarlarrya invivoeffectsofagpr30antagonist
AT hathawayhelenj invivoeffectsofagpr30antagonist
AT arterburnjeffreyb invivoeffectsofagpr30antagonist
AT opreatudori invivoeffectsofagpr30antagonist
AT prossnitzericr invivoeffectsofagpr30antagonist